Document is current
Any future updates will be listed below
-
Authors
Konig, Simon https://orcid.org/0000-0002-1052-0304
Jayarajan, Vignesh https://orcid.org/0000-0002-1185-3274
Wray, Selina https://orcid.org/0000-0003-3062-7050
Kamm, Roger https://orcid.org/0000-0002-7232-304X
Moeendarbary, Emad https://orcid.org/0000-0002-7019-3907
-
Funding
Funding for this research was provided by:
RCUK | Biotechnology and Biological Sciences Research Council (BB/V001418/1)
RCUK | Engineering and Physical Sciences Research Council (EP/W009889/1)
Cancer Research UK (C57744/A22057)
- License Information
-
More Information
Article History
Received: 17 January 2025
Accepted: 2 July 2025
First Online: 6 August 2025
Competing interests
: The authors declare the following competing interests: Emad Moeendarbary is the founder of BioRecode Ltd. RDK is a co-founder of AIM Biotech, a company that markets microfluidic technologies and receives research support from Amgen, AbbVie, Boehringer-Ingelheim, Daiichi-Sankyo, Novartis, Roche, Takeda, Eisai, EMD Serono and Visterra. None of these activities is related to the content of this article. The other authors declare no competing interests.
